Comparison of twice daily with thrice daily administered encainide for benign or potentially lethal ventricular arrhythmias.
The antiarrhythmic efficacy of encainide administered 2 (group A) or 3 times daily (group B) was evaluated in a randomized, placebo-controlled trial involving 101 patients with benign or potentially malignant ventricular arrhythmias. In group A, encainide was titrated at dosages of 35, 50 and 75 mg twice daily and in group B at dosages of 25, 35 and 50 mg 3 times daily. Drug efficacy, as judged by repeated ambulatory monitoring, was defined as greater than 75% reduction in ventricular premature complexes combined with a greater than 90% abolition of pairs and runs of nonsustained ventricular tachycardia. In group A, 27 of 52 patients (52%) had their arrhythmia suppressed by the drug compared with 34 of 49 (69%) in group B (difference not significant). There was a trend toward better arrhythmia control in group B if a total daily dose of greater than 100 mg was necessary for arrhythmia suppression. Side effects were frequent in both groups (24 vs 28%, difference not significant). Thus, encainide administered twice daily effectively suppresses ventricular arrhythmias in this patient population.
Hohnloser
S H
SH
Department of Cardiology, Freiburg University Hospital, Federal Republic of Germany.
Zabel
M
M
Zehender
M
M
Meinertz
T
T
Just
H
H
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000813:Anilides / Q000008:administration & dosage* / Q000627:therapeutic use; D000889:Anti-Arrhythmia Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D005117:Cardiac Complexes, Premature / Q000188:drug therapy*; D004334:Drug Administration Schedule; D004562:Electrocardiography; D016700:Encainide; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D008991:Monitoring, Physiologic; D015337:Multicenter Studies as Topic; D011897:Random Allocation; D013610:Tachycardia / Q000188:drug therapy*
D000813:Anilides; D000889:Anti-Arrhythmia Agents; D016700:Encainide